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Propositions | Stellingen 
Belonging to the thesis
Effectiveness and safety of medicines used in COPD patients
Pharmacoepidemiological studies
1. Prophylactic antibiotics, especially macrolides, are effective in preventing 
exacerbations of COPD, irrespective of the duration or schedule. 
2. Doxycycline is an effective antibiotic for treating COPD exacerbations in addition 
to systemic corticosteroids.
3. COPD patients with advanced age benefit more from antibiotics during 
exacerbations than younger patients, which may due to their susceptibility to 
bacterial infections.
4. Because an association is not equal to causation, we need valid study designs 
with more clinical information to further evaluate its causality and reduce 
confounding bias.
5. As polypharmacy is a very common problem in patients with COPD, more attention 
should be paid to potential DDIs to avoid related drug adverse events and 
treatment failure.
6. Varenicline as an effective medicine for smoking cessation does not appear to be 
associated with the risk of neuropsychiatric adverse events in both the general and 
COPD population.
7. Prescription sequence symmetry analysis is a self-controlled study design that can 
be used as an effective tool for post-market surveillance of medicines.
8. A river cuts through a rock, not because of its power, but because of its persistence. 
(James Watkins)
9. The hurrier I go, the behinder I get. (Lewis Carrol)
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